Latest Cannabis News

Peak Processing Limited has raised $2.72 million through a discounted share placement to fund growth and operational improvements in its Canadian and US markets. Key directors are backing the raise, signalling confidence in the company’s strategy.

Peak Processing Limited has completed a strategic rebrand and organisational restructure, securing new long-term manufacturing agreements and expanding product listings to strengthen its foothold in North America's regulated cannabis beverage markets.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Vitura Health has announced the departure of CEO Geoff Cockerill, appointing Chief Revenue Officer Ryan Tattle as interim leader while accelerating the search for a new CEO. Incoming CFO Andrew Cook will join ahead of schedule, signalling a renewed focus on operational and financial discipline.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.